Steven M. Offer

2.4k total citations · 1 hit paper
30 papers, 1.2k citations indexed

About

Steven M. Offer is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Steven M. Offer has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 17 papers in Oncology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Steven M. Offer's work include Colorectal Cancer Treatments and Studies (14 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Biochemical and Molecular Research (7 papers). Steven M. Offer is often cited by papers focused on Colorectal Cancer Treatments and Studies (14 papers), Pancreatic and Hepatic Oncology Research (9 papers) and Biochemical and Molecular Research (7 papers). Steven M. Offer collaborates with scholars based in United States, Switzerland and Netherlands. Steven M. Offer's co-authors include Robert B. Diasio, Natalie J. Wegner, Croix C. Fossum, Ursula Amstutz, Jan H.M. Schellens, Linda M. Henricks, Kelly E. Caudle, Jesse J. Swen, Teri E. Klein and Howard L. McLeod and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Steven M. Offer

29 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

2017 406 citations Ursula Amstutz, Linda M. Henricks et al. Clinical Pharmacology & Therapeutics profile →

Peers

Countries citing papers authored by Steven M. Offer

Since Specialization

Citations

This map shows the geographic impact of Steven M. Offer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven M. Offer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven M. Offer more than expected).

Fields of papers citing papers by Steven M. Offer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven M. Offer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven M. Offer. The network helps show where Steven M. Offer may publish in the future.

Co-authorship network of co-authors of Steven M. Offer

This figure shows the co-authorship network connecting the top 25 collaborators of Steven M. Offer. A scholar is included among the top collaborators of Steven M. Offer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven M. Offer. Steven M. Offer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Review of Neurologic and Developmental Conditions Associated with Pediatric Dihydropyrimidine Dehydrogenase Deficiency 2024 ·(unknown), Carlo R. Largiadèr, Steven M. Offer	0
2	Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD) 2024 ·eLife ·Ting Zhang, (unknown), Huixing Huang, Kelly J. Bouchonville, Amy S. Etheridge, (unknown), (unknown), (unknown), Zhiquan Wang, Federico Innocenti, Deborah Stroka, Robert B. Diasio, Carlo R. Largiadèr, Steven M. Offer	3
3	Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD) 2024 ·International Journal of Molecular Sciences ·(unknown), Angélique Sadlon, Ursula Amstutz, (unknown), Martin D. Berger, Sara Bastian, Steven M. Offer, Carlo R. Largiadèr	1
4	Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing 2023 ·Clinical and Translational Science ·Amy Turner, Cyrine E. Haidar, Wenjian Yang, Erin C. Boone, Steven M. Offer, Philip E. Empey, (unknown), (unknown), Gunter Scharer, Ulrich Broeckel, Andrea Gaedigk	23
5	Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy 2022 ·Cancers ·Robert B. Diasio, Steven M. Offer	23
6	Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity 2021 ·British Journal of Clinical Pharmacology ·(unknown), (unknown), Steven M. Offer, Didier Meulendijks, Christos T. Nakas, Robert B. Diasio, Stefano Fontana, Marc Wehrli, Stefan Schürch, Ursula Amstutz, Carlo R. Largiadèr	23
7	Defining Proximity Proteome of Histone Modifications by Antibody-Mediated Protein A-APEX2 Labeling 2021 ·Genomics Proteomics & Bioinformatics ·Xinran Li, Jiaqi Zhou, (unknown), Qing Wen, (unknown), (unknown), Yuan Gao, Kelly J. Bouchonville, Steven M. Offer, Kui Ming Chan, Zhiquan Wang, (unknown), Haiyun Gan	13
8	An integrated multi-omics approach to identify regulatory mechanisms in cancer metastatic processes 2021 ·Genome biology ·(unknown), Casey Hanson, (unknown), Kelly J. Bouchonville, Steven M. Offer, Saurabh Sinha	16
9	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance 2021 ·SHILAP Revista de lepidopterología ·Zhiquan Wang, (unknown), (unknown), Kelly J. Bouchonville, Robert B. Diasio, Steven M. Offer	7
10	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update breakdown → 2017 ·Clinical Pharmacology & Therapeutics ·Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia M. Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab	406
11	Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter 2016 ·Cancer Research ·(unknown), (unknown), Erin E. Tapper, Calvin R. Jerde, Garrett S. Dunlap, Shikshya Shrestha, Tarig Elraiyah, Steven M. Offer, Robert B. Diasio	18
12	Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy 2015 ·Clinical Cancer Research ·Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, Carlo R. Largiadèr	35
13	Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity 2014 ·Cancer Research ·Steven M. Offer, Croix C. Fossum, Natalie J. Wegner, (unknown), Gabriel L. Butterfield, Robert B. Diasio	134
14	A DPYD Variant (Y186C) Specific to Individuals of African Descent in a Patient With Life-Threatening 5-FU Toxic Effects: Potential for an Individualized Medicine Approach 2014 ·Mayo Clinic Proceedings ·Muhammad Wasif Saif, Adam M. Lee, Steven M. Offer, Kathleen McConnell, Valerie Relias, Robert B. Diasio	34
15	microRNAs miR-27a and miR-27b Directly Regulate Liver Dihydropyrimidine Dehydrogenase Expression through Two Conserved Binding Sites 2014 ·Molecular Cancer Therapeutics ·Steven M. Offer, Gabriel L. Butterfield, Calvin R. Jerde, Croix C. Fossum, Natalie J. Wegner, Robert B. Diasio	74
16	Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity 2013 ·Cancer Research ·Steven M. Offer, Natalie J. Wegner, Croix C. Fossum, Kangsheng Wang, Robert B. Diasio	96
17	A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity 2013 ·Clinical Pharmacology & Therapeutics ·Steven M. Offer, (unknown), Lori K. Mattison, Caroline Fossum, Natalie J. Wegner, Robert B. Diasio	80
18	Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy 2013 ·Leukemia ·Thomas E. Witzig, Gangqing Hu, Steven M. Offer, Linda Wellik, Jingjing Han, Mary Stenson, Ahmet Doǧan, Robert B. Diasio, Mamta Gupta	30
19	Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group 2011 ·BMC Cancer ·Harry H. Yoon, Paul J. Catalano, Kathleen M. Murphy, Todd C. Skaar, Santosh Philips, Mark Powell, Elizabeth A. Montgomery, Michael J. Hafez, Steven M. Offer, Geoffrey Liu, Stephen J. Meltzer, Xifeng Wu, Arlene A. Forastiere, Al B. Benson, Lawrence Kleinberg, Michael K. Gibson	20
20	Unique DNA Repair Gene Variations and Potential Associations with the Primary Antibody Deficiency Syndromes IgAD and CVID 2010 ·PLoS ONE ·Steven M. Offer, Qiang Pan‐Hammarström, Lennart Hammarström, Reuben S. Harris	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact